U.S. Distributes 726k COVID-19 Pills and Monoclonal Antibodies

The U.S. HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) today confirmed the continued implementation of the State and Territory-Coordinated Distribution System for COVID-19 related monoclonal antibodies (mAbs) and oral antivirals.

As of January 11, 2022, HHS/ASPR distributed 726,876​ doses to U.S. states, territories, and agencies for local allocations.

Of these doses, the oral antiviral Paxlovid (99,960) and Molinupivir (​399,920) were distributed.

And the four authorized mAbs, a total of 226,996 were distributed this week.

The HHS published the 'Outpatient administration guide for healthcare providers' on December 29, 2021. These COVID-19 products are being evaluated for effectiveness against the SARS-CoV-2 betacoronavirus variant known as Omicron.

In addition, the U.S. NIH OpenData portal publishes real-time data focused on Omicron.

Additional mAbs news is published on this Precision Vaccinations webpage.